Loading...

PHAXIAM Therapeutics S.A.

0QSS.L•LSE
Healthcare
Biotechnology
£0.10
£0.007(6.91%)

PHAXIAM Therapeutics S.A. (0QSS.L) Stock Overview

Explore PHAXIAM Therapeutics S.A.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 60.7/100

Key Financials

Market Cap1M
P/E Ratio-0.04
EPS (TTM)$-1.73
ROE-0.73%
Fundamental Analysis

AI Price Forecasts

1 Week$0.13
1 Month$0.10
3 Months$3.62
1 Year Target$0.03

0QSS.L Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of PHAXIAM Therapeutics S.A. (0QSS.L) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 25.16, suggesting the stock is in an oversold condition. Our forecasting models predict significant price movements, with a 12-month target of $0.03.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.04 and a market capitalization of 1M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Technical Indicators

25.16RSI (14)
-0.07MACD
20.64ADX
Stats data is not available for 0QSS.LStats details for 0QSS.L are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for 0QSS.LAnalyst Recommendations details for 0QSS.L are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa. The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023. PHAXIAM Therapeutics S.A. was incorporated in 2004 and is headquartered in Lyon, France.

CEO

Thibaut du Fayet

Employees

68

Headquarters

60 Avenue Rockefeller, Lyon

Founded

2014

Frequently Asked Questions

;